UY25801A1 - Procedimiento para preparar composiciones para el tratamiento de diabetes. - Google Patents

Procedimiento para preparar composiciones para el tratamiento de diabetes.

Info

Publication number
UY25801A1
UY25801A1 UY25801A UY25801A UY25801A1 UY 25801 A1 UY25801 A1 UY 25801A1 UY 25801 A UY25801 A UY 25801A UY 25801 A UY25801 A UY 25801A UY 25801 A1 UY25801 A1 UY 25801A1
Authority
UY
Uruguay
Prior art keywords
insulin sensitizer
treatment
plasma concentration
diabetes
procedure
Prior art date
Application number
UY25801A
Other languages
English (en)
Inventor
Jusko William
Benincosa Lisa
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842389&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25801(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of UY25801A1 publication Critical patent/UY25801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Un procedimiento para preparar una composición farmacéutica que comprende un sensibilizador de insulina tiazolidinadiónico y un vehículo farmacéuticamente aceptable para el mismo, adaptándose la composición para proporcionar una concentración plasmática del sensibilizador de insulina al menos igual a una concentración plasmática umbral del sensibilizador de insulina, cuyo procedimiento comprende formular el sensibilizador de insulina y el vehículo farmacéuticamente aceptable con objeto de proporcionar una concentración plasmática del sensibilizador de insulina al menos igual a una concentración plasmática umbral del sensibilizador de insulina. Dicha composición es útil en el tratamiento de la diabetes mellitus de tipo 2.
UY25801A 1998-11-12 1999-11-15 Procedimiento para preparar composiciones para el tratamiento de diabetes. UY25801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9824893.3A GB9824893D0 (en) 1998-11-12 1998-11-12 Novel method of treatment

Publications (1)

Publication Number Publication Date
UY25801A1 true UY25801A1 (es) 2000-08-21

Family

ID=10842389

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25797A UY25797A1 (es) 1998-11-12 1999-11-12 Método para el tratamiento de diabetes mellitus tipo 2
UY25801A UY25801A1 (es) 1998-11-12 1999-11-15 Procedimiento para preparar composiciones para el tratamiento de diabetes.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY25797A UY25797A1 (es) 1998-11-12 1999-11-12 Método para el tratamiento de diabetes mellitus tipo 2

Country Status (40)

Country Link
EP (2) EP1135128B1 (es)
JP (1) JP2003521455A (es)
KR (2) KR20070048279A (es)
CN (3) CN1235586C (es)
AP (2) AP1580A (es)
AR (2) AR029317A1 (es)
AT (1) ATE366573T1 (es)
AU (1) AU768303B2 (es)
BG (2) BG65577B1 (es)
BR (1) BR9915284A (es)
CA (1) CA2350425C (es)
CO (1) CO5150158A1 (es)
CY (1) CY1106892T1 (es)
CZ (1) CZ299801B6 (es)
DE (1) DE69936533T2 (es)
DK (1) DK1135128T3 (es)
DZ (1) DZ2938A1 (es)
EA (2) EA200700968A1 (es)
ES (1) ES2289833T3 (es)
GB (1) GB9824893D0 (es)
HK (1) HK1041202B (es)
HR (1) HRP20010344B1 (es)
HU (1) HUP0104262A3 (es)
IL (1) IL143088A0 (es)
MA (1) MA26759A1 (es)
MY (1) MY128347A (es)
NO (1) NO328391B1 (es)
NZ (1) NZ527132A (es)
OA (1) OA12193A (es)
PE (1) PE20001239A1 (es)
PL (1) PL349421A1 (es)
PT (1) PT1135128E (es)
RS (1) RS50130B (es)
SK (1) SK286357B6 (es)
TR (1) TR200101348T2 (es)
TW (1) TWI234456B (es)
UA (1) UA79730C2 (es)
UY (2) UY25797A1 (es)
WO (1) WO2000027341A2 (es)
ZA (1) ZA200103793B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
AU2002367154A1 (en) * 2001-12-21 2003-07-15 Smithkline Beecham Corporation Dosing regimen for ppar-gamma activators
WO2012074375A1 (en) * 2010-12-01 2012-06-07 N.V. Nutricia Prevention or treatment of overweight and obesity in type 2 diabetic patients

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469331A (ja) * 1990-07-10 1992-03-04 Asahi Chem Ind Co Ltd 徐放性エマルジョン製剤
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DK0601001T3 (da) * 1991-08-26 1997-10-20 Upjohn Co Flydende næringsmiddelprodukt indeholdende 3-guanidinopropionsyre.
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
US5478853A (en) * 1992-10-12 1995-12-26 Adir Et Compagnie Thazolidinedione compounds
CA2115587A1 (en) * 1993-02-18 1994-08-19 Hayato Kihara Styrene copolymers, polystyrene compositions, processes for producing styrene copolymers, and injection-molded articles
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
ATE376829T1 (de) * 1993-09-15 2007-11-15 Daiichi Sankyo Co Ltd Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes

Also Published As

Publication number Publication date
CN1235586C (zh) 2006-01-11
HK1041202B (zh) 2007-10-05
UY25797A1 (es) 2000-12-29
WO2000027341A3 (en) 2000-09-08
CN1354661A (zh) 2002-06-19
CA2350425C (en) 2009-06-02
JP2003521455A (ja) 2003-07-15
PL349421A1 (en) 2002-07-29
CZ299801B6 (cs) 2008-11-26
EP1135128B1 (en) 2007-07-11
MY128347A (en) 2007-01-31
AP2005003432A0 (en) 2005-12-31
CA2350425A1 (en) 2000-05-18
CY1106892T1 (el) 2012-01-25
NO20012301L (no) 2001-07-09
CZ20011656A3 (cs) 2002-06-12
AR029149A1 (es) 2003-06-18
NO20012301D0 (no) 2001-05-10
MA26759A1 (fr) 2004-12-20
EA200700968A1 (ru) 2008-06-30
ES2289833T3 (es) 2008-02-01
KR20010080440A (ko) 2001-08-22
DZ2938A1 (fr) 2004-03-15
KR20070048279A (ko) 2007-05-08
SK6422001A3 (en) 2001-12-03
BG105569A (en) 2002-01-31
HUP0104262A2 (en) 2002-08-28
SK286357B6 (sk) 2008-08-05
HRP20010344B1 (en) 2008-02-29
TWI234456B (en) 2005-06-21
IL143088A0 (en) 2002-11-10
GB9824893D0 (en) 1999-01-06
TR200101348T2 (tr) 2002-02-21
PE20001239A1 (es) 2000-12-24
WO2000027341A2 (en) 2000-05-18
CO5150158A1 (es) 2002-04-29
ATE366573T1 (de) 2007-08-15
CN1771943A (zh) 2006-05-17
RS50130B (sr) 2009-03-25
EA200100539A1 (ru) 2001-12-24
YU37401A (sh) 2005-07-19
NZ527132A (en) 2005-01-28
EP1135128A4 (en) 2003-07-16
PT1135128E (pt) 2007-10-12
BG110061A (bg) 2008-12-30
UA79730C2 (en) 2007-07-25
DE69936533T2 (de) 2008-03-13
AU1719600A (en) 2000-05-29
HRP20010344A2 (en) 2002-06-30
EP1135128A2 (en) 2001-09-26
BR9915284A (pt) 2002-02-13
HUP0104262A3 (en) 2003-06-30
DK1135128T3 (da) 2007-11-05
AR029317A1 (es) 2003-06-25
ZA200103793B (en) 2002-06-05
EA009192B1 (ru) 2007-12-28
AP1580A (en) 2006-02-24
AU768303B2 (en) 2003-12-04
CN101244062A (zh) 2008-08-20
EP1759698A1 (en) 2007-03-07
BG65577B1 (bg) 2009-01-30
HK1041202A1 (en) 2002-07-05
OA12193A (en) 2006-05-09
NO328391B1 (no) 2010-02-08
DE69936533D1 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
BR0015605A (pt) Composição e uso
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
EA200300323A1 (ru) ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ)
CO5090908A1 (es) Procedimiento para administrar peptidos insulinotropicos
YU37301A (sh) Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa
NO20100302L (no) Sammensetninger som inneholder organiske forbindelser
CO5261563A1 (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
AR002614A1 (es) Nuevo preparado medicamentoso estable para la produccion de aerosoles exentos de gas propulsor
YU10699A (sh) Upotreba glp-1, glp-1 analoga i glp-1 derivata za proizvodnju leka
CY1105254T1 (el) Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο
UY25800A1 (es) Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina.
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
ATE290858T1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
CO4940454A1 (es) Nuevo metodo de tratamiento
UY25801A1 (es) Procedimiento para preparar composiciones para el tratamiento de diabetes.
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
AR016350A1 (es) Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
ES2036560T3 (es) Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.
UY25103A1 (es) Composición para el tratamiento de diabetes mellitus
IL97855A0 (en) Bromide containing pharmaceutical compositions for treatment of psoriasis
CO4940457A1 (es) Composiciones farmaceuticas que comprenden sensibilizadores a insulina para tratamiento de la diabetes
ES2178382T3 (es) Compuestos de benciloxiprodigiosina.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110627